ANG LI to Aged
This is a "connection" page, showing publications ANG LI has written about Aged.
Connection Strength
0.523
-
Thrombosis risk prediction in lymphoma patients: A multi-institutional, retrospective model development and validation study. Am J Hematol. 2024 07; 99(7):1230-1239.
Score: 0.060
-
Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy. Am J Hematol. 2023 08; 98(8):1214-1222.
Score: 0.056
-
Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation. Am J Hematol. 2021 09 01; 96(9):1137-1146.
Score: 0.049
-
The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma. Ann Hematol. 2020 Jan; 99(1):121-126.
Score: 0.044
-
Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma. J Natl Compr Canc Netw. 2019 07 01; 17(7):840-847.
Score: 0.043
-
Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification. J Oncol Pharm Pract. 2020 Apr; 26(3):529-535.
Score: 0.043
-
Clinical features and outcomes in patients with thrombotic microangiopathy not associated with severe ADAMTS13 deficiency. Transfusion. 2017 09; 57(9):2151-2158.
Score: 0.037
-
Treatment with or without plasma exchange for patients with acquired thrombotic microangiopathy not associated with severe ADAMTS13 deficiency: a propensity score-matched study. Transfusion. 2016 08; 56(8):2069-77.
Score: 0.034
-
Development and validation of risk models for hospital-acquired bleeding in medical inpatients: the Medical Inpatients Thrombosis and Hemostasis (MITH) study. J Thromb Haemost. 2026 Feb; 24(2):418-430.
Score: 0.016
-
Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825. Neuro Oncol. 2025 Mar 07; 27(3):767-778.
Score: 0.016
-
Factors associated with venous thromboembolism pharmacoprophylaxis initiation in hospitalized medical patients: the Medical Inpatients Thrombosis and Hemostasis study. J Thromb Haemost. 2024 Dec; 22(12):3521-3531.
Score: 0.015
-
Discordance between aPTT and anti-Xa in monitoring heparin anticoagulation in mechanical circulatory support. ESC Heart Fail. 2024 Oct; 11(5):2742-2748.
Score: 0.015
-
Clonal Hematopoiesis Mutations in Patients with Lung Cancer Are Associated with Lung Cancer Risk Factors. Cancer Res. 2022 01 15; 82(2):199-209.
Score: 0.013
-
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. Eur Urol Oncol. 2021 06; 4(3):464-472.
Score: 0.012
-
Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. Br J Haematol. 2020 06; 189(6):1171-1181.
Score: 0.011
-
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer. 2020 03 15; 126(6):1208-1216.
Score: 0.011
-
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. Blood Adv. 2019 10 22; 3(20):3062-3069.
Score: 0.011
-
Direct oral anticoagulant- versus vitamin K antagonist-related gastrointestinal bleeding: Insights from a nationwide cohort. Am Heart J. 2019 10; 216:117-124.
Score: 0.011
-
Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignancies. Transfusion. 2019 05; 59(5):1773-1780.
Score: 0.010
-
Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative. Br J Haematol. 2015 Dec; 171(5):836-44.
Score: 0.008
-
Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. Hematol Oncol. 2016 Sep; 34(3):147-53.
Score: 0.008